Thiopurine S-methyltransferase (TPMT) Activity is Better Determined by Biochemical Assay Versus Genotyping in the Jewish Population

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2014 Jan 7

PMID 24390675

Citations 2

Authors

Yair Kasirer

Rephael Mevorach

Paul Renbaum

Nurit Algur

Devora Soiferman

Rachel Beeri

Yelana Rachman

Reeval Segel

Dan Turner

Affiliations

Soon will be listed here.

Abstract

Background: Thiopurine S-methyltransferase (TPMT) is a key enzyme that deactivates thiopurines, into their inactive metabolite, 6-methylmercaptopurine. Intermediate and low TPMT activity may lead to leukopenia following thiopurine treatment. The aim of this study was to determine TPMT activity and TPMT alleles (genotype-phenotype correlation) in Jews, aiming to develop an evidence-based pharmacogenetic assay for this population.

Methods: TPMT activity was determined in 228 Jewish volunteers by high performance liquid chromatography. Common allelic variants in the Caucasian population [TPMT*2 (G238C), TPMT *3A (G460A and A719G), TPMT* 3B (G460A) and TPMT*3C (A719G)] were tested. Phenotype-genotype correlation was examined and discordant cases were fully sequenced to identify novel genetic variants.

Results: Mean TPMT activity was 15.4 ± 4 U/ml red blood cells (range 1-34). Intermediate activity was found in 33/228 (14%) subjects and absent activity was found in one sample (0.4%). Only eight individuals (3.5% of the entire cohort and 24% of those with intermediate/low activity) were identified as carriers of a TPMT genetic variant, all of whom had the TPMT*3A allele. Sequencing the entire TPMT coding region and splice junctions in the remainder of the discordant cases did not reveal any novel variants.

Conclusion: Genotyping TPMT in Jews yields a much lower rate of variants than identified in the general Caucasian population. We conclude that a biochemical assay to determine TPMT enzymatic activity should be performed in Jews before starting thiopurine treatment in order to identify low activity subjects.

Citing Articles

Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.

Roy L, Zur R, Uleryk E, Carew C, Ito S, Ungar W Pharmacogenomics. 2016; 17(6):633-56.

PMID: 27020704 PMC: 4931919. DOI: 10.2217/pgs.16.12.

Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y Clin Exp Immunol. 2015; 181(2):362-72.

PMID: 25846055 PMC: 4516452. DOI: 10.1111/cei.12640.

References

Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H . Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55(10):1423-31. PMC: 1856436. DOI: 10.1136/gut.2005.074930. View

Seidman E . Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003; 3 Suppl 1:S30-8. View

Cuffari C, Dassopoulos T, Turnbough L, Thompson R, Bayless T . Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004; 2(5):410-7. DOI: 10.1016/s1542-3565(04)00127-2. View

Dubinsky M, Reyes E, Ofman J, Chiou C, Wade S, Sandborn W . A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100(10):2239-47. DOI: 10.1111/j.1572-0241.2005.41900.x. View

Eaton J, Silveira M, Pardi D, Sinakos E, Kowdley K, Luketic V . High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011; 106(9):1638-45. PMC: 3168684. DOI: 10.1038/ajg.2011.156. View

Boson W, Romano-Silva M, Correa H, Falcao R, Teixeira-Vidigal P, De Marco L . Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J. 2003; 3(3):178-82. DOI: 10.1038/sj.tpj.6500175. View

Dewit O, Starkel P, Roblin X . Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest. 2010; 40(11):1037-47. DOI: 10.1111/j.1365-2362.2010.02346.x. View

Ronen O, Cohen S, Rund D . Evaluating frequencies of thiopurine S-methyl transferase (TPMT) variant alleles in Israeli ethnic subpopulations using DNA analysis. Isr Med Assoc J. 2011; 12(12):721-5. View

Nygaard U, Toft N, Schmiegelow K . Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther. 2004; 75(4):274-81. DOI: 10.1016/j.clpt.2003.12.001. View

10.

Efrati E, Adler L, Krivoy N, Sprecher E . Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population. Eur J Clin Pharmacol. 2008; 65(3):257-62. DOI: 10.1007/s00228-008-0590-7. View

11.

Schutz E, Gummert J, Mohr F, Armstrong V, Oellerich M . Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?. Ther Drug Monit. 1996; 18(3):228-33. DOI: 10.1097/00007691-199606000-00002. View

12.

Ansari A, Hassan C, Duley J, Marinaki A, Seed P, Meenan J . Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16(10):1743-50. DOI: 10.1046/j.1365-2036.2002.01353.x. View

13.

LOWENTHAL A, Meyerstein N . Thiopurine methyltransferase activity in the Jewish population of Israel. Eur J Clin Pharmacol. 2001; 57(1):43-6. DOI: 10.1007/s002280100267. View

14.

Osterman M, Kundu R, Lichtenstein G, Lewis J . Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130(4):1047-53. DOI: 10.1053/j.gastro.2006.01.046. View

15.

Weinshilboum R, Sladek S . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32(5):651-62. PMC: 1686086. View

16.

Khalil M, Erb N, Khalil P, Escherich G, Janka-Schaub G . Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 821(1):105-11. DOI: 10.1016/j.jchromb.2005.04.028. View

17.

Tai H, Krynetski E, Yates C, Loennechen T, Fessing M, Krynetskaia N . Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996; 58(4):694-702. PMC: 1914689. View

18.

Hindorf U, Appell M . Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis. 2012; 6(6):655-9. DOI: 10.1016/j.crohns.2011.11.014. View

19.

Oh K, Anis A, Bae S . Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford). 2003; 43(2):156-63. DOI: 10.1093/rheumatology/keh001. View

20.

Elske van den Akker-van Marle M, Gurwitz D, Detmar S, Enzing C, Hopkins M, de Mesa E . Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006; 7(5):783-92. DOI: 10.2217/14622416.7.5.783. View